Certara, Inc. (NASDAQ:CERT) Receives Consensus Rating of “Hold” from Analysts

Certara, Inc. (NASDAQ:CERT) has been assigned an average recommendation of “Hold” from the fourteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $11.10.

CERT has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. Morgan Stanley reduced their price objective on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. KeyCorp reduced their target price on shares of Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, January 8th. Barclays reiterated an “equal weight” rating and issued a $8.00 price target on shares of Certara in a research note on Friday, March 6th. Finally, Stephens decreased their target price on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, December 12th.

Institutional Trading of Certara

A number of institutional investors have recently bought and sold shares of CERT. Corient Private Wealth LLC bought a new position in Certara during the fourth quarter worth $100,000. T. Rowe Price Investment Management Inc. grew its stake in shares of Certara by 580,097.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 829,683 shares of the company’s stock worth $7,310,000 after acquiring an additional 829,540 shares in the last quarter. nVerses Capital LLC bought a new stake in Certara in the 4th quarter worth about $184,000. Toronto Dominion Bank grew its holdings in shares of Certara by 186.9% in the fourth quarter. Toronto Dominion Bank now owns 83,939 shares of the company’s stock valued at $739,000 after acquiring an additional 54,677 shares in the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in shares of Certara during the 4th quarter valued at $256,000. Institutional investors own 73.96% of the company’s stock.

Certara Trading Up 1.4%

NASDAQ:CERT opened at $6.65 on Monday. The company has a market cap of $1.06 billion, a P/E ratio of -665.00 and a beta of 1.50. Certara has a twelve month low of $6.04 and a twelve month high of $15.38. The business has a 50 day moving average price of $7.98 and a two-hundred day moving average price of $9.60. The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The business had revenue of $103.65 million during the quarter, compared to analyst estimates of $103.23 million. During the same quarter last year, the business earned $0.15 earnings per share. Certara’s revenue for the quarter was up 3.2% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, analysts expect that Certara will post 0.28 EPS for the current fiscal year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.